Jefferies Maintains a 'Buy' on Synta Pharma. (SNTA); Still See Significant Upside

Jefferies maintains a 'Buy' on Synta Pharma. (NASDAQ: SNTA) price target of $15.00.

Analyst, Thomas Wei, said, "SNTA's CEO provided an update on the ganetespib development program. Next events include a planned second interim analysis of GALAXY Phase 2b data and finalization of the Phase 3 design to both occur in 2H12. We remain buyers and believe there could be significant upside with more mature follow-up in GALAXY."

For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.

Shares of Synta Pharma. closed at $6.60 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Downgrades Aegis Vopak Terminals (AEGISVOP:IN) to Hold
• Herc Holding (HRI) PT Raised to $218 at Wells Fargo
• Jefferies Starts Aditya Birla Real Estate (ABREL:IN) at Buy